Litcius/Paper detail

Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Claudia Kedor, Joachim Listing, Jan Zernicke, Anja Weiß, Frank Behrens, Norbert Blank, Jörg Henes, Joern Kekow, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Eva Seipelt, Christof Specker, Eugen Feist

2020Annals of the Rheumatic Diseases99 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCanakinumabPlaceboDouble blindAdult-onset Still's diseaseHomeopathyPhysical therapyClinical trialArthritisAlternative medicineInternal medicineDiseasePathologyAnakinraAutoimmune and Inflammatory Disorders ResearchInflammation biomarkers and pathwaysImmune Cell Function and Interaction
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial | Litcius